Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2023-06-07
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 8); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 110); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-15 (study day 205); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-20 (study day 210); relationship: N; serious criteria: hospitalization
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.